AB Science Confirms the Filing for the Marketing Authorization Application to the European Medicines Agency of Masitinib in the Treatment of Pancreatic Cancer

Published: Oct 16, 2012

PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), confirms the filing to EMA for the Marketing Authorization Application for masitinib in the treatment of pancreatic cancer.

Back to news